HIV-Therapeutics/Clinical Trials & Psychiatric Pathogenesis Program
Overview
The HIV-Therapeutics /Clinical Trials & Psychiatric Pathogenesis Program supports: (1) preclinical to clinical research on existing and novel drug targets; (2) the development of novel approaches for delivering drugs to the central nervous system; and (3) creative and original research that has as its goal the movement of new treatments / therapeutic strategies to the clinic. This program fosters a strong and diverse base in preclinical discovery and places a new emphasis on the translation of innovative treatment concepts to the clinic. Basic and clinical studies on HAART-related neurotoxicities are encouraged.
Areas of Emphasis
- Identify the etiology and pathogenesis of HIV-induced psychiatric disorders.
- Assess the impact of HIV infection on preexisting psychiatric condition.
- Study comorbid disease progression of HIV and psychiatric illnesses.
- Identify the etiology of, and biomarkers for, a vulnerable brain in the context of HIV (viral) infection and emotional and stress-regulated systems.
- Identify and characterize genetic, molecular and cellular factors that mediate immune and nervous system interactions and contribute to the variability in neuro-related disease progression.
Contact
Jeymohan Joseph, Ph.D.
Program Chief
6001 Executive Boulevard, Room 6202, MSC 9619
301-443-3012, jjeymoha@mail.gov
